Complete Loss of EPCAM Immunoexpression Identifies EPCAM Deletion Carriers in MSH2-Negative Colorectal Neoplasia

Simple Summary Colorectal carcinomas from patients with Lynch syndrome (LS) due to EPCAM deletions show loss of MSH2 expression. The aim of our study was to evaluate the usefulness of EPCAM expression in identifying carriers of EPCAM deletion among patients with MSH2-negative lesions. MSH2 and EPCAM immunohistochemistry was performed in a large series of lesions (190) composed of malignant and benign neoplasms as well as precursor lesions of different organs from 71 patients with suspected LS due to MSH2 alterations. Germ-line analysis confirmed LS in 68 patients due to MSH2 mutations (53) and EPCAM deletions (15). Among colorectal lesions with lack of MSH2 expression, only 17 were EPCAM-negative and belonged to patients with EPCAM deletions. We confirm that loss of EPCAM expression identifies EPCAM deletion carriers with 100% specificity and we recommend adding EPCAM IHC to the algorithm of MSH2-negative colorectal neoplasia. Abstract The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to MSH2 alterations. LS was confirmed in 68 patients, 53 with MSH2 mutations and 15 with EPCAM 3′-end deletions. Tissue microarrays were constructed with human normal tissues and their malignant counterparts to assist in the evaluation of EPCAM staining. Among 154 MSH2-negative lesions, 17 were EPCAM-negative, including 10 CRC and 7 colorectal polyps, and 5 of them showed only isolated negative glands. All lesions showing a lack of EPCAM expression belonged to patients with EPCAM 3′-end deletions. EPCAM IHC is a useful screening tool, with 100% specificity to identify LS patients due to EPCAM 3′-end deletions in MSH2-negative CRC and MSH2-negative colorectal polyps.

[1]  T. Kuopio,et al.  Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas , 2020, Oncotarget.

[2]  I. Nagtegaal,et al.  Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis , 2019, European Journal of Human Genetics.

[3]  M. Frey,et al.  Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? , 2019, Cancer.

[4]  D. Evans,et al.  The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis , 2019, Genetics in Medicine.

[5]  C. Boland,et al.  EPCAM mutation update: Variants associated with congenital tufting enteropathy and Lynch syndrome , 2018, Human mutation.

[6]  E. Van Cutsem,et al.  Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. , 2018, European journal of cancer.

[7]  K. Farsalinos,et al.  Tobacco-specific nitrosamines: A literature review. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  S. Thibodeau,et al.  DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome , 2018, Modern Pathology.

[9]  W. Alexander.  ESMO World Congress on Gastrointestinal Cancer. , 2017, P & T : a peer-reviewed journal for formulary management.

[10]  K. Sheahan,et al.  The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. , 2017, Critical reviews in oncology/hematology.

[11]  Teruhiko Yoshida,et al.  Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis , 2017, Modern Pathology.

[12]  Teruhiko Yoshida,et al.  Cytoplasmic MSH2 immunoreactivity in a patient with Lynch syndrome with an EPCAM–MSH2 fusion , 2017, Histopathology.

[13]  Nicolas Wentzensen,et al.  Carcinogenic human papillomavirus infection , 2016, Nature Reviews Disease Primers.

[14]  A. Arrospide,et al.  Prevalencia de alteración de expresión nuclear de proteínas reparadoras con inmunohistoquímica sobre adenomas con displasia de alto grado y características asociadas a dicho riesgo en un estudio de base poblacional , 2016 .

[15]  Teruhiko Yoshida,et al.  Mismatch repair deficiency in Lynch syndrome‐associated colorectal adenomas is more prevalent in older patients , 2016, Histopathology.

[16]  H. Lynch,et al.  Lynch syndrome in the 21st century: clinical perspectives. , 2016, QJM : monthly journal of the Association of Physicians.

[17]  Wendy K Chung,et al.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing , 2015, Genetics in Medicine.

[18]  N. Cho,et al.  Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma , 2015, Oncotarget.

[19]  A. Arrospide,et al.  [Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study]. , 2016, Gastroenterologia y hepatologia.

[20]  A. Ristimäki,et al.  DNA hypermethylation appears early and shows increased frequency with dysplasia in Lynch syndrome-associated colorectal adenomas and carcinomas , 2015, Clinical Epigenetics.

[21]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[22]  Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case , 2015, Familial Cancer.

[23]  Randall W Burt,et al.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. , 2014, Gastroenterology.

[24]  A. Ariza,et al.  Mismatch repair protein immunohistochemistry: a useful population screening strategy for Lynch syndrome. , 2014, Human pathology.

[25]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[26]  Eline Beert,et al.  EPCAM germline and somatic rearrangements in lynch syndrome: identification of a novel 3′EPCAM deletion , 2013, Genes, chromosomes & cancer.

[27]  G. Capellá,et al.  Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. , 2013, Human pathology.

[28]  C. Toulas,et al.  Colon‐specific phenotype in Lynch syndrome associated with EPCAM deletion , 2012, Clinical genetics.

[29]  A. Voigt,et al.  The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors , 2012, Modern Pathology.

[30]  Aung Ko Win,et al.  Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry , 2012, Modern Pathology.

[31]  E. Kuipers,et al.  Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome , 2012, The Journal of pathology.

[32]  C. Boland,et al.  Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps , 2012, Cancer Prevention Research.

[33]  M. Sanz,et al.  Frequency of Rearrangements in Lynch Syndrome Cases Associated with MSH2: Characterization of a New Deletion Involving both EPCAM and the 5′ Part of MSH2 , 2011, Cancer Prevention Research.

[34]  P. Went,et al.  EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.

[35]  A. Voigt,et al.  Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Julie O. Culver,et al.  Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. , 2011, The Lancet. Oncology.

[37]  H. Lynch,et al.  EPCAM deletions, Lynch syndrome, and cancer risk. , 2011, The Lancet. Oncology.

[38]  P. Laird,et al.  Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. , 2011, The Journal of molecular diagnostics : JMD.

[39]  T. Tuohy,et al.  Hereditary and familial colon cancer. , 2010, Gastroenterology.

[40]  M. Kloor,et al.  Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.

[41]  F. Nagengast,et al.  In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response , 2009, Histopathology.

[42]  H. Hollema,et al.  Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[43]  Mari Mino-Kenudson,et al.  Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. , 2009, The Journal of molecular diagnostics : JMD.

[44]  Z. Szentirmay,et al.  Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome , 2009, Human mutation.

[45]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[46]  S. Nelson,et al.  Identification of EpCAM as the gene for congenital tufting enteropathy. , 2008, Gastroenterology.

[47]  E. Schmelzer,et al.  EpCAM expression in normal, non-pathological tissues. , 2008, Frontiers in bioscience : a journal and virtual library.

[48]  A. Lindblom,et al.  Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer , 2005, Modern Pathology.

[49]  M. Kloor,et al.  Microsatellite analysis of hereditary nonpolyposis colorectal cancer-associated colorectal adenomas by laser-assisted microdissection: correlation with mismatch repair protein expression provides new insights in early steps of tumorigenesis. , 2005, The Journal of molecular diagnostics : JMD.

[50]  P. Eilers,et al.  The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. , 2004, Gastroenterology.

[51]  B. Leggett,et al.  DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer , 2000, Gut.